High-level Research Projects of China-Japan Friendship Hospital
Conditions
Interventions
Shenxian Quyu Decoction Group :Western medicine standardized treatment combined with Shenxian Quyu Decoction
Western medicine standardized treatment combined Group :Western medicine standardized treatment combined
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Be between the ages of 18-75; 2. Meet the Western medical diagnostic criteria for stable coronary heart disease; 3. Patients with stable coronary heart disease within 1-6 months after coronary heart disease intervention; 4. Complete the overall treatment plan after PCI; 5. Patients with qi deficiency and blood stasis syndrome who meet the diagnostic criteria of traditional Chinese medicine; 6. Have a clear understanding of the content and purpose of the study, voluntarily participate in the study, and sign the informed consent form by themselves.
Exclusion criteria
Exclusion criteria: 1. There are contraindications of cardiopulmonary exercise test; 2. Plan for coronary artery bypass grafting or heart transplantation; 3. Within 3 months before admission: stroke, transient ischemic attack; carotid artery or other major vascular surgery; persistent ventricular tachycardia or ventricular fibrillation; 4. Ventricular arrhythmia was not controlled effectively (antiarrhythmic drugs or implantable defibrillator were ineffective; 5. Uncorrected primary obstruction or severe reflux valvular disease, non dilated (restrictive) or hypertrophic cardiomyopathy; 6. Patients with second or third degree heart block or sick sinus syndrome, without permanent pacemaker, who need implantable devices for heart failure; 7. Obstructive or bronchospasmodic lung disease (such as asthma, bronchitis, etc.) requires oral or inhaled bronchodilator or hormone therapy; 8. Pregnant or lactating women and women who plan to become pregnant during the trial period; 9. Cancer or other systemic diseases, the expected survival time is less than 12 months; 10. Use other clinical trial drugs or participate in medical device test within 30 days before enrollment; 11. The researchers considered that they could not participate in the study after clinical evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak oxygen consumption change rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome score;Seattle angina questionnaire;EuroQol-5 Dimensions;Routine blood test;Liver and kidney function;Blood fat;Electrocardiogram; | — |
Countries
China
Contacts
Public ContactLu Xiaoyan
China-Japan Friendship Hospital
Outcome results
None listed